Compass Pathways, a UK-based psychedelic company, has partnered with New Jersey-based healthcare network Hackensack Meridian Health to further research on the use of psilocybin in mental health treatments.
This collaboration will leverage Hackensack Meridian Health’s well-established expertise in mental health to better design the usage and delivery model of COMP360, Compass’ investigational psilocybin treatment for mental health issues.
Compass plans to extend the application of psilocybin beyond treating PTSD to other conditions, such as treatment-resistant depression and anorexia nervosa. Results from current research studies are expected to be released between summer 2024 and mid-2025.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.